Ladenburg analyst Michael Higgins downgraded Marinus Pharmaceuticals to Neutral from Buy.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRNS:
- Is MRNS a Buy, Before Earnings?
- Class Action Lawsuit against Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS)
- Marinus Pharmaceuticals announces China NMPA approval for ganaxolone
- Shareholders that lost money on Marinus Pharmaceuticals, Inc.(MRNS) Urged to Join Class Action – Contact Levi & Korsinsky LLP to Learn More
- Marinus:RAISE didn’t achieve statistical significance on one endpoint